Preferred Label : ROR1 CAR-specific Autologous T-Lymphocytes;
NCIt synonyms : Chimeric Anti-ROR1 T-cell Receptor-expressing Autologous T-lymphocytes; Autologous ROR1-CAR-T Cells; ROR1-CAR-T;
NCIt definition : A mixture of two T-lymphocyte preparations expressing a chimeric antigen receptor
(CAR) consisting of an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1)
single chain variable fragment (scFv) fused to either the co-stimulatory signaling
domain cluster of differentiation 28 (CD28), and the zeta chain of the T-cell receptor
(TCR)/CD3 complex (CD3-zeta) (ROR1CD28zeta), or the co-stimulatory signaling domain
cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor
(TCR)/CD3 complex (CD3-zeta) (ROR1CD137zeta), with potential immunomodulating and
antineoplastic activities. Upon simultaneous administration of the two T-lymphocyte
populations ROR1CD28zeta and ROR1CD137zeta , the ROR1 CAR-specific autologous T-lymphocytes
are directed to tumor cells expressing ROR1, which may result in a selective toxicity
against, and lysis of ROR1-expressing tumor cells. CD28, a T-cell surface-associated
co-stimulatory molecule, is required for full T-cell activation, proliferation, and
survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and
signaling after recognition of ROR1. ROR1, also known as neurotrophic tyrosine kinase,
receptor-related 1, is expressed during embryogenesis and by certain leukemias.;
NCI Metathesaurus CUI : CL474110;
Origin ID : C117237;
UMLS CUI : C3896611;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
